BioLife Solutions (NASDAQ:BLFS) had its price objective boosted by B. Riley from $20.00 to $25.50 in a research report report published on Friday, The Fly reports. They currently have a buy rating on the medical equipment provider’s stock.

A number of other analysts have also recently commented on BLFS. TheStreet cut shares of BioLife Solutions from a b- rating to a c rating in a report on Thursday, March 12th. Maxim Group upped their price objective on BioLife Solutions from $18.00 to $26.00 and gave the stock a buy rating in a research note on Wednesday, July 8th. Northland Securities reiterated a buy rating and set a $28.00 target price (up from $24.00) on shares of BioLife Solutions in a research report on Wednesday, July 8th. Oppenheimer restated a buy rating on shares of BioLife Solutions in a research report on Wednesday, May 6th. Finally, ValuEngine cut BioLife Solutions from a buy rating to a hold rating in a research report on Wednesday, April 29th. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company has an average rating of Buy and a consensus target price of $23.28.

Shares of BLFS opened at $19.40 on Friday. The firm has a market capitalization of $620.08 million, a P/E ratio of 47.32 and a beta of 1.53. BioLife Solutions has a one year low of $7.37 and a one year high of $21.18. The business has a fifty day moving average of $16.70 and a 200 day moving average of $14.17.

BioLife Solutions (NASDAQ:BLFS) last announced its earnings results on Thursday, May 14th. The medical equipment provider reported $0.06 earnings per share (EPS) for the quarter. BioLife Solutions had a return on equity of 4.55% and a net margin of 97.57%. The business had revenue of $12.16 million for the quarter, compared to analysts’ expectations of $12.09 million.

In other news, VP Aby J. Mathew sold 10,000 shares of the business’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $13.40, for a total value of $134,000.00. Following the transaction, the vice president now owns 223,157 shares of the company’s stock, valued at $2,990,303.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael Rice sold 18,750 shares of the company’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $9.66, for a total transaction of $181,125.00. Following the transaction, the chief executive officer now owns 233,489 shares of the company’s stock, valued at approximately $2,255,503.74. The disclosure for this sale can be found here. Over the last 90 days, insiders bought 3,065,953 shares of company stock worth $37,618,224 and sold 946,031 shares worth $13,984,044. 22.30% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Casdin Capital LLC lifted its stake in BioLife Solutions by 1.6% in the 4th quarter. Casdin Capital LLC now owns 2,468,571 shares of the medical equipment provider’s stock worth $39,941,000 after purchasing an additional 40,000 shares in the last quarter. Sentinel Pension Advisors Inc. purchased a new position in shares of BioLife Solutions during the first quarter valued at about $10,450,000. Park West Asset Management LLC increased its holdings in shares of BioLife Solutions by 12.5% in the first quarter. Park West Asset Management LLC now owns 979,406 shares of the medical equipment provider’s stock worth $9,304,000 after purchasing an additional 108,495 shares during the last quarter. BlackRock Inc. lifted its position in shares of BioLife Solutions by 7.2% in the first quarter. BlackRock Inc. now owns 595,328 shares of the medical equipment provider’s stock worth $5,656,000 after buying an additional 39,861 shares in the last quarter. Finally, Tarsadia Capital LLC bought a new position in BioLife Solutions during the first quarter valued at approximately $4,536,000. Institutional investors own 46.95% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Recommended Story: What is the S&P/ASX 200 Index?

The Fly

Analyst Recommendations for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.